This remarkable peptide is making waves with rising popularity among beauty enthusiasts and those seeking a safer alternative to UV exposure
Available from: Weghuber D, Barrett T, Barrientos-Prez M, Gies I, Hesse D, Jeppesen OK, et al
The single key differentiator is receptor count: retatrutide's third receptor (glucagon) raises the efficacy ceiling but demands slower titration, while semaglutide and tirzepatide trade a lower ceiling for MHRA authorisation and deeper safety data
Typically, a DAR of 34 is targeted, as illustrated in Panel A of Fig
HK was an employee of Eli Lilly and Company at the time of the study
The Times article went on to describe some patient anecdotes indicating that microdosing a GLP-1 had worked for them, praising the approach